journal
MENU ▼
Read by QxMD icon Read
search

Blood Cancer Journal

journal
https://www.readbyqxmd.com/read/29789584/rtk-ras-pathway-mutation-is-enriched-in-myeloid-sarcoma
#1
LETTER
Mihong Choi, Yoon Kyung Jeon, Choong-Hyun Sun, Hong-Seok Yun, Junshik Hong, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon, Youngil Koh
No abstract text is available yet for this article.
May 23, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29748532/semaphorin-4d-correlates-with-increased-bone-resorption-hypercalcemia-and-disease-stage-in-newly-diagnosed-patients-with-multiple-myeloma
#2
Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Dimitrios Christoulas, Tina Bagratuni, Marios Bakogeorgos, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Efstathios Kastritis, Meletios A Dimopoulos
Multiple myeloma (MM) is characterized by bone destruction due to increased bone resorption and decreased bone formation. Semaphorin 4D (CD100, Sema4D) is expressed by osteoclasts, binds to its receptor Plexin-B1, and acts as a mediator of osteoclast-osteoblast interaction that ultimately inhibits osteoblastic bone formation. Preclinical data suggest that Sema4D/Plexin-B1 pathway is implicated in MM-induced bone disease. However, there is no information on the role of Sema4D in MM patients. Thus, we evaluated Sema4D and Plexin-B1 in six myeloma cells lines in vitro; in the bone marrow plasma (BMP) and serum of 72 newly diagnosed symptomatic MM (NDMM) patients and in 25 healthy controls...
May 11, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29712896/daratumumab-lenalidomide-and-dexamethasone-in-east-asian-patients-with-relapsed-or-refractory-multiple-myeloma-subgroup-analyses-of-the-phase-3-pollux-study
#3
Kenshi Suzuki, Meletios A Dimopoulos, Naoki Takezako, Shinichiro Okamoto, Atsushi Shinagawa, Morio Matsumoto, Hiroshi Kosugi, Sung-Soo Yoon, Shang-Yi Huang, Xiang Qin, Ming Qi, Shinsuke Iida
In the phase 3 POLLUX study, daratumumab plus lenalidomide and dexamethasone (DRd) significantly reduced the risk of progression/death and induced deeper responses vs. lenalidomide and dexamethasone alone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM). We report a subgroup analysis of East Asian (Japanese, Korean, and Taiwanese) patients from POLLUX based on a longer follow-up of 24.7 months. Median progression-free survival was not reached (NR) for DRd vs. 13.8 months for Rd (hazard ratio [HR], 0...
May 1, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29712895/waldenstr%C3%A3-m-macroglobulinemia-treatment-algorithm-2018
#4
REVIEW
Morie A Gertz
Waldenström macroglobulinemia is often an indolent disorder, and many patients are candidates for observation with careful monitoring. For symptomatic patients, one must distinguish between those patients whose symptoms are related to immunologic manifestations associated with the IgM monoclonal protein and those that have symptoms related to progressive marrow and nodal infiltration with lymphoplasmacytic lymphoma. In Waldenström macroglobulinemia, the driver for therapy in the majority of patients is progressive anemia, secondary to bone marrow replacement by lymphoplasmacytic lymphoma...
May 1, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29618788/dnmt3a-r882-associated-hypomethylation-patterns-are-maintained-in-primary-aml-xenografts-but-not-in-the-dnmt3a-r882c-oci-aml3-leukemia-cell-line
#5
LETTER
David Chen, Matthew Christopher, Nichole M Helton, Ian Ferguson, Timothy J Ley, David H Spencer
No abstract text is available yet for this article.
April 4, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29618787/prognostic-value-of-serum-vascular-endothelial-growth-factor-and-hematological-responses-in-patients-with-newly-diagnosed-poems-syndrome
#6
LETTER
Hao Zhao, Hao Cai, Chen Wang, Xu-Fei Huang, Xin-Xin Cao, Lu Zhang, Dao-Bin Zhou, Jian Li
No abstract text is available yet for this article.
April 4, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29618722/incorporation-of-mutations-in-five-genes-in-the-revised-international-prognostic-scoring-system-can-improve-risk-stratification-in-the-patients-with-myelodysplastic-syndrome
#7
Hsin-An Hou, Cheng-Hong Tsai, Chien-Chin Lin, Wen-Chien Chou, Yuan-Yeh Kuo, Chieh-Yu Liu, Mei-Hsuan Tseng, Yen-Ling Peng, Ming-Chih Liu, Chia-Wen Liu, Xiu-Wen Liao, Liang-In Lin, Ming Yao, Jih-Luh Tang, Hwei-Fang Tien
Gene mutations have not yet been included in the 2016 WHO classification and revised International Prognostic Scoring System (IPSS-R), which are now widely utilized to discriminate myelodysplastic syndrome (MDS) patients regarding risk of leukemia evolution and overall survival (OS). In this study, we aimed to investigate whether integration of gene mutations with other risk factors could further improve the stratification of MDS patients. Mutational analyses of 25 genes relevant to myeloid malignancies in 426 primary MDS patients showed that mutations of CBL, IDH2, ASXL1, DNMT3A, and TP53 were independently associated with shorter survival...
April 4, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29563517/bone-marrow-cd8-t-cells-express-high-frequency-of-pd-1-and-exhibit-reduced-anti-leukemia-response-in-newly-diagnosed-aml-patients
#8
LETTER
Bei Jia, Liru Wang, David F Claxton, W Christopher Ehmann, Witold B Rybka, Shin Mineishi, Syed Rizvi, Hiroko Shike, Michael Bayerl, Todd D Schell, Raymond J Hohl, Hong Zheng
No abstract text is available yet for this article.
March 21, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29563506/a-multiple-myeloma-specific-capture-sequencing-platform-discovers-novel-translocations-and-frequent-risk-associated-point-mutations-in-igll5
#9
Brian S White, Irena Lanc, Julie O'Neal, Harshath Gupta, Robert S Fulton, Heather Schmidt, Catrina Fronick, Edward A Belter, Mark Fiala, Justin King, Greg J Ahmann, Mary DeRome, Elaine R Mardis, Ravi Vij, John F DiPersio, Joan Levy, Daniel Auclair, Michael H Tomasson
Multiple myeloma (MM) is a disease of copy number variants (CNVs), chromosomal translocations, and single-nucleotide variants (SNVs). To enable integrative studies across these diverse mutation types, we developed a capture-based sequencing platform to detect their occurrence in 465 genes altered in MM and used it to sequence 95 primary tumor-normal pairs to a mean depth of 104×. We detected cases of hyperdiploidy (23%), deletions of 1p (8%), 6q (21%), 8p (17%), 14q (16%), 16q (22%), and 17p (4%), and amplification of 1q (19%)...
March 21, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29563490/mir-451a-abrogates-treatment-resistance-in-flt3-itd-positive-acute-myeloid-leukemia
#10
LETTER
Rosanna H E Krakowsky, Alexander A Wurm, Dennis Gerloff, Christiane Katzerke, Daniela Bräuer-Hartmann, Jens-Uwe Hartmann, Franziska Wilke, Christian Thiede, Carsten Müller-Tidow, Dietger Niederwieser, Gerhard Behre
No abstract text is available yet for this article.
March 21, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29559616/the-cd20-specific-engineered-toxin-antibody-mt-3724-exhibits-lethal-effects-against-mantle-cell-lymphoma
#11
LETTER
Shengjian Huang, Changying Jiang, Hui Zhang, Taylor Bell, Hui Guo, Yang Liu, Yixin Yao, Dongfeng Zeng, Makhdum Ahmed, Krystle Nomie, Leo Zhang, Michael Wang
No abstract text is available yet for this article.
March 20, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29531217/infrequent-occurrence-of-tet1-tet3-and-asxl2-mutations-in-myelodysplastic-myeloproliferative-neoplasms
#12
LETTER
Terra L Lasho, Rangit Vallapureddy, Christy M Finke, Abhishek Mangaonkar, Naseema Gangat, Rhett Ketterling, Ayalew Tefferi, Mrinal M Patnaik
No abstract text is available yet for this article.
March 12, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29523783/real-world-data-on-prognosis-and-outcome-of-primary-plasma-cell-leukemia-in-the-era-of-novel-agents-a-multicenter-national-study-by-the-greek-myeloma-study-group
#13
Eirini Katodritou, Evangelos Terpos, Sossana Delimpasi, Maria Kotsopoulou, Eurydiki Michalis, Chrysanthi Vadikolia, Marie-Christine Kyrtsonis, Argiris Symeonidis, Nikolaos Giannakoulas, Chrissa Vadikolia, Michalis Michael, Christina Kalpadakis, Theodora Gougopoulou, Chrystalla Prokopiou, Georgia Kaiafa, Dimitrios Christoulas, Maria Gavriatopoulou, Evlampia Giannopoulou, Vasiliki Labropoulou, Evgenia Verrou, Efstathios Kastritis, Pavlina Konstantinidou, Achilles Anagnostopoulos, Meletios A Dimopoulos
We have studied the efficacy and the prognostic impact of novel agents in 50 primary plasma cell leukemia (pPCL) patients registered in our database. Eighty percent of patients were treated upfront with novel agent-based combinations; 40% underwent autologous stem cell transplantation (ASCT). Objective response rate was 76; 38% achieved at least very good partial response (≥vgPR) and this correlated significantly with bortezomib-based therapy plus ASCT. At the time of evaluation, 40 patients had died. Early mortality rate (≤1 month) was 6%...
March 9, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29520024/a-systematic-classification-of-death-causes-in-multiple-myeloma
#14
LETTER
Elias K Mai, Eva-Maria Haas, Stephan Lücke, Martin Löpprich, Christina Kunz, Maria Pritsch, Petra Knaup-Gregori, Marc S Raab, Jana Schlenzka, Uta Bertsch, Jens Hillengass, Hartmut Goldschmidt
No abstract text is available yet for this article.
March 8, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29515114/momelotinib-therapy-for-myelofibrosis-a-7-year-follow-up
#15
Ayalew Tefferi, Daniela Barraco, Terra L Lasho, Sahrish Shah, Kebede H Begna, Aref Al-Kali, William J Hogan, Mark R Litzow, Curtis A Hanson, Rhett P Ketterling, Naseema Gangat, Animesh Pardanani
One-hundred Mayo Clinic patients with high/intermediate-risk myelofibrosis (MF) received momelotinib (MMB; JAK1/2 inhibitor) between 2009 and 2010, as part of a phase 1/2 trial (NCT00935987); 73% harbored JAK2 mutations, 16% CALR, 7% MPL, 44% ASXL1, and 18% SRSF2. As of July 2017, MMB was discontinued in 91% of the patients, after a median treatment duration of 1.4 years. Grade 3/4 toxicity included thrombocytopenia (34%) and liver/pancreatic test abnormalities (<10%); grade 1/2 peripheral neuropathy occurred in 47%...
March 7, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29515104/detailed-analysis-of-clonal-evolution-and-cytogenetic-evolution-patterns-in-patients-with-myelodysplastic-syndromes-mds-and-related-myeloid-disorders
#16
Julie Schanz, Naciye Cevik, Christa Fonatsch, Friederike Braulke, Katayoon Shirneshan, Ulrike Bacher, Detlef Haase
Clonal cytogenetic evolution (CE) (i.e., acquisition of new chromosomal aberrations over time) is relevant for the progression of myelodysplastic syndromes (MDS). We performed detailed analysis of CE in 729 patients with MDS and related disorders. Patients with CE showed shorter survival (median OS 18.0 versus 53.9 months; P < 0.01), higher leukemic transformation rate (48.0% versus 21.4%; P < 0.01) and shorter intervals to leukemic transformation (P < 0.01). Two main CE patterns were detected: early versus late CE (median onset 5...
March 7, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29535299/benefit-risk-profile-of-cytoreductive-drugs-along-with-antiplatelet-and-antithrombotic-therapy-after-transient-ischemic-attack-or-ischemic-stroke-in-myeloproliferative-neoplasms
#17
Valerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro, Paola Guglielmelli, Alessandra Iurlo, Maria Chiara Finazzi, Elisa Rumi, Francisco Cervantes, Elena Maria Elli, Maria Luigia Randi, Martin Griesshammer, Francesca Palandri, Massimiliano Bonifacio, Juan-Carlos Hernandez-Boluda, Rossella Cacciola, Palova Miroslava, Giuseppe Carli, Eloise Beggiato, Martin H Ellis, Caterina Musolino, Gianluca Gaidano, Davide Rapezzi, Alessia Tieghi, Francesca Lunghi, Giuseppe Gaetano Loscocco, Daniele Cattaneo, Agostino Cortelezzi, Silvia Betti, Elena Rossi, Guido Finazzi, Bruno Censori, Mario Cazzola, Marta Bellini, Eduardo Arellano-Rodrigo, Irene Bertozzi, Parvis Sadjadian, Nicola Vianelli, Luigi Scaffidi, Montse Gomez, Emma Cacciola, Alessandro M Vannucchi, Tiziano Barbui
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs. The composite incidence of recurrent TIA and IS, acute myocardial infarction (AMI), and cardiovascular (CV) death was 4.21 and 19.2%, respectively at one and five years after the index event, an estimate unexpectedly lower than reported in the general population. Patients tended to replicate the first clinical manifestation (hazard ratio, HR: 2...
February 28, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29531316/rapid-real-time-pathology-review-for-ecog-acrin-1412-a-novel-and-successful-paradigm-for-future-lymphoma-clinical-trials-in-the-precision-medicine-era
#18
Rebecca L King, Grzegorz S Nowakowski, Thomas E Witzig, David W Scott, Richard F Little, Fangxin Hong, Randy D Gascoyne, Brad S Kahl, William R Macon
ECOG/ACRIN 1412 (E1412) is a randomized, phase II open-label study of lenalidomide/RCHOP vs. RCHOP alone in adults with newly diagnosed de novo diffuse large B-cell lymphoma (DLBCL) and requires NanoString gene expression profiling (GEP) for cell-of-origin testing. Because of high ineligibility rate on retrospective expert central pathology review (ECPR), real-time (RT) ECPR was instituted to confirm diagnosis and ensure adequate tissue for GEP prior to study enrollment. Goal was notification of eligibility within 2 working days (WD)...
February 28, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29531285/defining-cure-in-multiple-myeloma-a-comparative-study-of-outcomes-of-young-individuals-with-myeloma-and-curable-hematologic-malignancies
#19
Praful Ravi, Shaji K Kumar, James R Cerhan, Matthew J Maurer, David Dingli, Stephen M Ansell, S Vincent Rajkumar
Advances in therapy in recent years have led investigators to challenge the dogma that multiple myeloma (MM) is incurable. We assessed overall (OS) and progression-free survival (PFS) of young patients ( ≤ 50 years) with MM and compared outcomes with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and Hodgkin lymphoma (HL). All patients ≤ 50 years with newly diagnosed MM (n = 212), FL (n = 168), DLBCL (n = 195), and HL (n = 233) between 1 January 2005 and 31 December 2015 were included...
February 28, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29483508/protease-nexin-1-prevents-growth-of-human-b-cell-lymphoma-via-inhibition-of-sonic-hedgehog-signaling
#20
LETTER
Xiangke Xin, Yunchuan Ding, Ying Yang, Xing Fu, Jianfeng Zhou, Chad M McKee, Ruth J Muschel, Robert P Gale, Jane F Apperley, Danmei Xu
No abstract text is available yet for this article.
February 26, 2018: Blood Cancer Journal
journal
journal
43747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"